Since the discovery of actionable activating epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement in lung cancer, thoracic oncologists have led the way in comprehensive genomic profiling (CGP) of solid malignancies for precision medicine. The gene discussed is EGFR; the disease is lung carcinoma.